Answers are grounded in this paper and cite their sources.
Improved survival after chemotherapy was found in patients with TP53(Wt) tumors harboring the R72 variant. MDM2 overexpression in TP53(Wt) tumors predicted good response to MDM2 antagonists, irrespective of R72P or SNP309 status. Thus, detailed TP53 and MDM2 genotype analyses prior to systemic therapy are recommended.
No takes yet. Share an insight, caveat, or question.
Ohnstad et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: